ArticleCureus2025
Methotrexate Shortages and Their Impact on Chronic Inflammatory Rheumatic Disease Management: Results From a National Survey of Moroccan Rheumatologists.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the impact of methotrexate (MTX) shortages on the management of chronic inflammatory rheumatic diseases (CIRD) in Morocco and their consequences on patient care. MATERIAL AND
methodsWe conducted a cross-sectional online survey among Moroccan rheumatologists. A structured Google Forms (Google Inc., Mountain View, CA, USA) questionnaire was emailed to rheumatologists, divided into five sections: sociodemographic data, MTX indications and prescription methods, patient-reported reasons for stopping MTX, consequences of stopping MTX, and possible solutions.
resultsThe survey was completed by 153 rheumatologists (mean age 42.9 ± 12.7 years, 84.8% female, mean length of practice 13.8±11 years). Overall, 98.7% considered MTX as the conventional disease-modifying antirheumatic drug (cDMARD) of choice for treating CIRD, with 84.3% prescribing it primarily for rheumatoid arthritis. The main reason for MTX discontinuation was unavailability of treatment (96.1%), and 97.4% of rheumatologists reported difficulties in prescribing due to recurrent stock shortages. Consequences included increased use of higher daily doses of oral corticosteroids (94%), higher rates of hospitalization for corticosteroid bolus infusions (79%), therapeutic escalation to biologics in biologic-naïve patients (67.3%), and reduced effectiveness of current biologic therapy (44.6%).
conclusionThis survey highlights the significant impact of MTX shortages on CIRD management, driving reliance on expensive biologics and deteriorating patients' and families' quality of life. Urgent action is needed to ensure a continuous MTX supply.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.